- Home
- AMAT vs GILD Comparison
AMAT vs GILD Comparison
Compare AMAT & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAT
- GILD
- Stock Information
- Founded
- AMAT 1967
- GILD 1987
- Country
- AMAT United States
- GILD United States
- Employees
- AMAT N/A
- GILD N/A
- Industry
- AMAT Semiconductors
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMAT Technology
- GILD Health Care
- Exchange
- AMAT Nasdaq
- GILD Nasdaq
- Market Cap
- AMAT 126.7B
- GILD 129.9B
- IPO Year
- AMAT N/A
- GILD 1992
- Fundamental
- Price
- AMAT $169.79
- GILD $113.00
- Analyst Decision
- AMAT Buy
- GILD Buy
- Analyst Count
- AMAT 22
- GILD 25
- Target Price
- AMAT $200.91
- GILD $110.17
- AVG Volume (30 Days)
- AMAT 8.0M
- GILD 8.3M
- Earning Date
- AMAT 05-15-2025
- GILD 04-24-2025
- Dividend Yield
- AMAT 1.08%
- GILD 2.79%
- EPS Growth
- AMAT N/A
- GILD 1118.07
- EPS
- AMAT 8.22
- GILD 4.73
- Revenue
- AMAT $28,089,000,000.00
- GILD $28,735,000,000.00
- Revenue This Year
- AMAT $8.04
- GILD $1.55
- Revenue Next Year
- AMAT $5.72
- GILD $3.69
- P/E Ratio
- AMAT $20.65
- GILD $23.91
- Revenue Growth
- AMAT 5.99
- GILD 4.68
- 52 Week Low
- AMAT $123.74
- GILD $62.69
- 52 Week High
- AMAT $255.89
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- AMAT 63.31
- GILD 63.34
- Support Level
- AMAT $153.47
- GILD $108.31
- Resistance Level
- AMAT $165.54
- GILD $111.62
- Average True Range (ATR)
- AMAT 3.91
- GILD 2.50
- MACD
- AMAT 0.14
- GILD 0.61
- Stochastic Oscillator
- AMAT 88.94
- GILD 93.45
About AMAT Applied Materials Inc.
Applied Materials Inc is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).